Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco WilderHill Clean Energy ETF (PBW) vs Repligen Corporation Common Stock (RGEN) Price & Performance

Invesco WilderHill Clean Energy ETFTrade
Repligen Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Invesco WilderHill Clean Energy ETF vs Repligen Corporation Common Stock — how do they compare? Invesco WilderHill Clean Energy ETF trades at $25.75 (market cap $315.85M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 35.3× Invesco WilderHill Clean Energy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 47 Days and Repligen Corporation Common Stock for 0 Days on average.

PBWRGEN
Market Cap
$315.85M$11.14B
Volume
452,8331,259,263
Sector
Sector/ThematicHealth
52-Week High
$46.99$194.57
52-Week Low
$25.77$102.87
Typical Hold Time
47 Days0 Days
Enterprise Value
—$11.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco WilderHill Clean Energy ETF

The Invesco WilderHill Clean Energy ETF (PBW) trades at $27.33, down 0.33% on the day, with a bearish technical signal driven by moving averages. Key financial ratios such as P/E and P/S are not applicable for this ETF. Recent news highlights institutional selling, with IFP Advisors cutting its stake by 96.3% in Q2 2026 (SEC filing, September 18, 2026).

The outlook is cautious due to technical weakness and institutional outflows. Opportunities lie in the clean energy theme amid global investment, but risks include high volatility and concentrated portfolio strategy. The ETF's performance is tied to sector sentiment rather than traditional corporate fundamentals.

Repligen Corporation Common Stock

RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.

Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PBW
0% Buy100% Sell
Avg holding period · 47 Days
RGEN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Invesco WilderHill Clean Energy ETF

PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.

Read more on PBW →

About Repligen Corporation Common Stock

Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.

Read more on RGEN →